Want to see CCEL full AI Analyst Report?
Top Page
Cryo-Cell International
(CCEL)
Select Model
Select Model
Rating:50Neutral
Price Target:
$4.50
▲(30.06% Upside)
Action:Reiterated
Date:08/22/26
The score is held back primarily by weak financial performance: steep revenue decline, ongoing net losses, and a highly concerning negative equity position. Technicals provide partial support with price trading above key moving averages and a positive MACD, but overbought readings (RSI/Stoch) add near-term risk. Valuation is not compelling given the negative P/E and lack of a stated dividend yield.
Positive Factors
Positive cash generation
Positive operating and free cash flow provide internal funding for operations and reduce dependence on external capital. This is a meaningful strength because cash generation remains positive despite reported losses, although its durability depends on stabilizing revenue.
Negative Factors
Sharp revenue contraction
A sustained top-line decline would weaken the customer base and reduce the pool of new upfront enrollments that can feed future storage revenue. It also limits operating leverage, making it harder for the company to absorb fixed laboratory, marketing, and facility costs.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive cash generation
Positive operating and free cash flow provide internal funding for operations and reduce dependence on external capital. This is a meaningful strength because cash generation remains positive despite reported losses, although its durability depends on stabilizing revenue.
Read all positive factors
Cryo-Cell International (CCEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$33.70M
Dividend YieldN/A
Average Volume (3M)4.07K
Price to Earnings (P/E)―
Beta (1Y)0.15
Revenue Growth-2.69%
EPS Growth-1365.07%
CountryUS
Employees74
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.29
Shares Outstanding8,062,650
10 Day Avg. Volume4,683
30 Day Avg. Volume4,066
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.73
Price to Sales (P/S)1.02
P/FCF Ratio6.12
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)$30.04M
Cryo-Cell International Business Overview & Revenue Model
Company Description
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical...
How the Company Makes Money
Cryo-Cell primarily makes money by charging customers for (1) upfront fees and (2) recurring storage fees associated with preserving newborn stem-cell–rich biological materials. Key revenue streams typically include: (a) collection/processing fees...
Cryo-Cell International Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
24
Negative
Cash Flow
71
Positive
| Breakdown | TTM | Nov 2025 | Feb 2025 | Nov 2023 | Feb 2023 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.13M | 31.57M | 31.99M | 31.34M | 30.34M | 28.88M |
| Gross Profit | 24.07M | 24.19M | 24.04M | 22.90M | 21.54M | 19.90M |
| EBITDA | 578.36K | 1.10M | 1.42M | -10.42M | 6.65M | 5.32M |
| Net Income | -2.47M | -2.43M | 402.10K | -9.52M | 2.77M | 2.08M |
Balance Sheet | ||||||
| Total Assets | 60.71M | 61.73M | 64.68M | 61.22M | 64.89M | 60.66M |
| Cash, Cash Equivalents and Short-Term Investments | 3.16M | 3.30M | 3.50M | 980.25K | 1.72M | 8.34M |
| Total Debt | 8.96M | 11.56M | 12.93M | 10.90M | 11.61M | 2.82M |
| Total Liabilities | 78.46M | 80.33M | 77.89M | 72.25M | 66.41M | 56.48M |
| Stockholders Equity | -17.76M | -18.61M | -13.22M | -11.03M | -1.52M | 4.18M |
Cash Flow | ||||||
| Free Cash Flow | 6.11M | 5.25M | 2.41M | 1.28M | -8.60M | 974.92K |
| Operating Cash Flow | 6.32M | 5.48M | 6.01M | 8.92M | 8.57M | 7.93M |
| Investing Cash Flow | 869.10K | -975.33K | -4.88M | -8.14M | -15.28M | -6.95M |
| Financing Cash Flow | -6.81M | -4.75M | -979.12K | -2.07M | 147.86K | -3.07M |
Cryo-Cell International Technical Analysis
Positive
3.46
Price Trends
3.59
Positive
3.57
Positive
3.57
Positive
Market Momentum
0.19
Negative
73.44
Negative
86.33
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCEL, the sentiment is Positive. The current price of 3.46 is below the 20-day moving average (MA) of 3.69, below the 50-day MA of 3.59, and below the 200-day MA of 3.57, indicating a bullish trend. The MACD of 0.19 indicates Negative momentum. The RSI at 73.44 is Negative, neither overbought nor oversold. The STOCH value of 86.33 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCEL.
Cryo-Cell International Risk Analysis
Cryo-Cell International disclosed 41 risk factors in its most recent earnings report. Cryo-Cell International reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cryo-Cell International Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $527.26M | 12.50 | 14.27% | ― | 0.64% | 19.57% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $33.70M | -15.50 | 14.18% | ― | -2.69% | -1365.07% | |
49 Neutral | $22.79M | -0.04 | 5.73% | ― | 20.26% | 69.68% | |
45 Neutral | $6.57M | -0.66 | ― | ― | ― | ― |
* Healthcare Sector Average
CCEL
Cryo-Cell International
4.56
-0.02
-0.44%
CCM
Concord Medical Services
5.29
-0.18
-3.29%
SRTA
Strata Critical Medical
6.24
1.82
41.18%
NIVF
NewGenIvf Group
0.58
-314.42
-99.82%
BMGL
Basel Medical Group Ltd
5.30
-18.46
-77.69%
AIDX
20/20 Biolabs, Inc.
0.55
-23.30
-97.68%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.